TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.
https://www.fiercebiotech.com/biotech/tscan-lays-30-workforce-halts-phase-1-solid-tumor-t-cell-receptor-trial